Position in HROW
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,815,757
+$1,749,157 QoQ
Shares Held
193,300
+86.9% QoQ
Ownership
0.519%
of shares outstanding
% of Portfolio
2.25%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2024
5 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in HROW Over Time
Shares Held
Position Value (USD)
Derivatives in HROW
reported options exposure · as of Mar 31, 2026CallValue
$176,300
CallShares
5,000
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Crawford Fund Management, LLC holds $15,632,183 across 2 Drug Manufacturers - Specialty & Generic names. HROW ranks #2 (43.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
14,868 | $8,816,426 | |
| 2 | HROW |
Harrow, Inc.
This page
|
193,300 | $6,815,757 |
All Filings in HROW
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $176,300 | 5,000 | Call | Sole | 2026-05-15 | |
| 2026-03-31 | $6,815,757 | 193,300 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $392,000 | 8,000 | Call | Other | 2026-02-17 | |
| 2025-12-31 | $5,066,600 | 103,400 | Shares | Sole | 2026-02-17 | |
| 2024-12-31 | $335,500 | 10,000 | Call | Sole | 2025-02-14 | |
| 2024-09-30 | $449,600 | 10,000 | Call | Sole | 2024-11-14 | |
| 2024-06-30 | $208,900 | 10,000 | Call | Sole | 2024-08-14 | |
| No filing history on record for this holder in this stock. | ||||||